Key points are not available for this paper at this time.
Introduction: Evaluate the temporal changes in and relationship between skeletal endpoints in response to palopegteriparatide (TransCon PTH), a prodrug with sustained release of PTH(1-34), in individuals with chronic hypoparathyroidism.
Tsourdi et al. (Wed,) studied this question.